Clinical Trial Update: BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated. [Phase 4]

View source ↗

Summary

This Phase 4 trial assessed substituting raltegravir for nucleoside reverse transcriptase inhibitors in a boosted atazanavir HIV regimen. The study evaluated sa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• ATAZANAVIR (atazanavir)
• Raltegravir (raltegravir)

Snippet

Sponsor: Community Research Initiative of New England | Conditions: HIV | Phase 4 | Status: COMPLETED | Results posted: 2013-03-11